Skip to content
drillr.ai
Sign up

01093.HK

CSPC Pharmaceutical Group Limited

HKSE · Healthcare · Drug Manufacturers - General · CN

HKD 7.87
−2.18%
Ask drillr

  • Oct 29, 2026, 03:12 UTC

    CSPC Pharmaceutical Group Ltd. announced that the Phase I SYS6077-001 trial of its SYS6077 injection for advanced malignant tumors had formally started at its first research center in China.

    Source:

  • Oct 27, 2026, 08:12 UTC

    Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.

    Source:

  • Oct 27, 2026, 04:12 UTC

    Hong Kong-listed shares showed varied moves at midday, including Xiaomi Corp. down 4.2%, Lenovo Group Ltd. up 5.8%, and Duality Biotherapeutics, Inc. down 29.4%.

    Source:

  • Oct 23, 2026, 01:30 UTC

    CSPC Pharmaceutical Group Ltd. initiated a Phase II clinical trial of SYH2066 tablets for respiratory syncytial virus infection at the first study center in China.

    Source:

  • Oct 22, 2026, 04:12 UTC

    Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.

    Source:

  • Oct 21, 2026, 01:29 UTC

    CSPC Pharmaceutical Group Ltd. announced that its SYH2083 eye-drop Phase I clinical trial for dry eye disease has formally started in China.

    Source:

  • Oct 13, 2026, 09:09 UTC

    BlackRock, Inc. increased its long position in CSPC Pharmaceutical Group Ltd. from 4.55% to 5.16%.

    Source:

  • Sep 30, 2026, 08:12 UTC

    Hong Kong stocks closed higher on September 30, 2026, with the Hang Seng Index up 89 points or 0.4% at 24,613 and the Hang Seng Tech Index up 4 points or 0.1% at 4,253, on turnover of HK$187.158 billion.

    Source:

  • Sep 30, 2026, 04:12 UTC

    Hong Kong stock indices closed the morning session mixed, with the Hang Seng Index down 10 points at 24,513 and the Hang Seng Tech Index down 6 points at 4,243, while CSPC Pharmaceutical rose over 5% and GenScript Biotech hit a new high.

    Source:

  • Sep 21, 2026, 05:00 UTC

    Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.

    Source:

  • Sep 21, 2026, 02:51 UTC

    Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

    Source:

  • Sep 21, 2026, 02:17 UTC

    Hong Kong stocks fell early then rebounded on Monday, with the Hang Seng Index dropping 13.86 points to 24,736.92 before rising over 145 points to 24,896.43, while biotech and pharmaceutical shares gained and Alibaba rose 2% and Alibaba Health fell 5%.

    Source:

  • Sep 18, 2026, 01:27 UTC

    CSPC Group and AstraZeneca Continental signed a deal agreement on August 3 to establish a joint venture providing biopharmaceutical contract manufacturing organization services, with CSPC holding 51% and AstraZeneca Continental 49%; the concentration filing entered the public comment period on September 18, 2026.

    Source:

  • Sep 1, 2026, 10:35 UTC

    Shenzhen Sineuro Medical Technology Co., Ltd., a subsidiary of Sinomed, received a Class III medical device registration certificate from China's National Medical Products Administration for its delivery-type balloon dilation catheter, valid until August 30, 2031.

    Source:

  • Aug 28, 2026, 05:58 UTC

    CSPC Pharmaceutical Group established a health innovation technology company in Shijiazhuang, with a business scope including medical device sales and pharmaceutical wholesale and retail.

    Source:

  • Aug 28, 2026, 02:07 UTC

    Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 27, 2026, 09:14 UTC

    Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.

    Source:

  • Aug 25, 2026, 11:16 UTC

    CSPC Pharmaceutical Group received FDA approval to conduct clinical trials in the United States for its recombinant respiratory syncytial virus vaccine (SYS 6057).

    Source:

  • Aug 20, 2026, 10:07 UTC

    Shiyao Jingfeng announced its first-half 2026 results, reporting a net profit of 5.8689 million yuan, turning around from a loss of 32.5674 million yuan in the same period last year.

    Source:

  • Aug 20, 2026, 06:48 UTC

    Shares of CSPC Pharmaceutical Group surged over 15% in morning trading on August 20, 2026, driven by positive Phase 3 results of Moderna and Merck's personalized mRNA cancer therapy intismeran.

    Source:

  • Aug 20, 2026, 04:36 UTC

    CSPC Pharmaceutical Group declared an interim dividend of HK$0.18 per share, an increase of 28.6% from HK$0.14 in the same period last year.

    Source:

  • Aug 20, 2026, 04:18 UTC

    CSPC Pharmaceutical Group reported first-half revenue of 18.59 billion yuan, exceeding the market estimate of 14.63 billion yuan.

    Source:

  • Aug 18, 2026, 13:58 UTC

    China Securities Regulatory Commission Hunan Bureau ordered Ye Xianglun, a concert party of Ye Xiangwu (a shareholder holding over 5% of Shiyao Jingfeng), to buy back improperly reduced shares and remit the price difference to the listed company.

    Source:

  • Aug 18, 2026, 13:04 UTC

    China's National Medical Products Administration accepted the new drug application for KN026 combined with HB1801 for first-line treatment of advanced breast cancer, developed by CSPC Group's subsidiary Jinmantebio and Alphamab Oncology, and granted priority review.

    Source:

  • Aug 5, 2026, 09:51 UTC

    CSPC Group received a US$10 million milestone payment from AstraZeneca on 5 August 2026 under the strategic research and development collaboration agreement, related to AstraZeneca's exercise of the license option for one of the PCC projects.

    Source:

  • Aug 5, 2026, 08:35 UTC

    CSPC Group and AstraZeneca signed a joint venture contract to establish a joint venture.

    Source:

  • Aug 4, 2026, 10:07 UTC

    Alphamab Oncology and CSPC Pharmaceutical Group subsidiary Jinmantebio's new drug application for anlotinib combined with chemotherapy for neoadjuvant treatment of HER2-positive breast cancer has been accepted by China's National Medical Products Administration and included in priority review.

    Source:

  • Jul 31, 2026, 10:03 UTC

    CSPC Group announced that its recombinant respiratory syncytial virus vaccine (SYS 6057) has been approved by China's National Medical Products Administration to conduct clinical trials in China.

    Source:

  • Jul 15, 2026, 02:58 UTC

    China's National Medical Products Administration (CDE) granted breakthrough therapy designation to KN026 (Anni Tuo monoclonal antibody) combined with HB1801 for first-line treatment of HER2-positive breast cancer.

    Source:
Page 1Next →